Clinical trial

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

NCT04837209

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-07-21

PhasePHASE2

Study timeline

Study start (actual)2021-07-21Date precision: day

Registry last updated2026-06-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Triple Negative Breast Cancerunresolved

Interventions

NiraparibDRUG · verified · RxNorm: niraparib

DostarlimabDRUG · verified · RxNorm: dostarlimab

Radiation therapyRADIATION

Sponsors & collaborators

Massachusetts General Hospitallead sponsor

Sibley Memorial Hospitalcollaborator

Duke Universitycollaborator

University of Pennsylvaniacollaborator

Mapped research locations

BostonMassachusetts, United States1 PhiladelphiaPennsylvania, United States1 DurhamNorth Carolina, United States1 Washington D.C.District of Columbia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04837209 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.